Phlebotomist

Phlebotomist at MCKESSON

• draw blood and other related clinical duties for patients enrolled on clinical trials
• access, flush, and de-access ports
• perform peripheral and port lab draws
• obtain blood and other samples, vital signs, and EKGs from patients
• prepare study supplies/source documents necessary for obtaining lab samples prior to patient treatment
• utilize electronic medical record (EMR) for source documentation
• verify of all prepared lab kits against EMR
• report all known regimen issues to the Protocol Excellence team for correction
• assist in Sarah Cannon Research Institute Oncology Partners (SCRI OP) Infusion Room with collection of blood and other samples, vital signs, and EKGs from patients
• assist physicians with procedures, as needed
• assist patients with activities of daily living (ADLs), as needed (i.e. bathroom, relocating within the clinic, etc.)
• perform buccal swabs on pharmacokinetics (PK) patients
• collect all pharmacokinetic blood draws on patients in the hospital
• complete and submit FMLA paperwork
• perform Guardant 360, Myriad, and Tempus collections and complete all necessary paperwork for submission
• ship these tests
• deliver STAT labs to the CMC laboratory for processing
• track and document tumor lesion photos for all required patients
• respond to queries generated from study sponsor and contract lab regarding patient/sample data
• interface with SCRI OP and CMC laboratory colleagues regarding labs for research patients
• ensure that all research patients have correct lab kits prior to patients' visits

• High school diploma, preferably a Technical School Certification in phlebotomy/lab
• Knowledge of OSHA requirements for safe handling of blood and bodily fluids
• Knowledge of HIPAA
• Experience with venipuncture and Blood Processing
• Experience with EKG Collections
• Experience with port Accessing, Flushing, and De-Accessing
• Experience in research is preferred
• Current BLS Certification

• 401k matching
• Health insurance
• Flight privileges

Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. In 2022, SCRI formed a joint venture with former US Oncology Research to expand clinical trial access across the country. It has conducted more than 750 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. SCRI’s research network brings together more than 1,300 physicians who are actively enrolling patients into clinical trials at more than 250 locations in 24 states across the U.S.